$8.90
0.355[4.15%]
At close: Apr 18
$8.90
0[0.00%]
After Hours: 9:01AM EDT
Oncternal Therapeutics
(NASDAQ:ONCT)Latest News for Oncternal Therapeutics Stock (NASDAQ:ONCT)
Oncternal Therapeutics Stock (NASDAQ: ONCT)
Categories: All
Thursday, April 18, 2024
Monday, April 15, 2024
Tuesday, April 02, 2024
Thursday, March 07, 2024
- Recap: Oncternal Therapeutics Q4 EarningsBenzinga Insights - Mar 7, 2024, 4:25PM
- Oncternal Therapeutics Q4 2023 GAAP EPS $(3.110) Misses $(3.070) Estimate, Sales $297.000K Beat $137.500K EstimateBenzinga Newsdesk - Mar 7, 2024, 4:23PM
- Earnings Scheduled For March 7, 2024Benzinga Insights - Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
Monday, January 29, 2024
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - Jan 29, 2024, 4:31PM
- American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For MondayAvi Kapoor - Jan 29, 2024, 7:34AM
- HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Raises Price Target to $30Benzinga Newsdesk - Jan 29, 2024, 6:32AM
Monday, January 22, 2024
Monday, January 08, 2024
Friday, January 05, 2024
Thursday, January 04, 2024
Wednesday, December 27, 2023
- Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Dec 27, 2023, 2:11PM
- Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Dec 27, 2023, 8:14AM
- HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $2 Price TargetBenzinga Newsdesk - Dec 27, 2023, 6:10AM
Tuesday, December 26, 2023
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Dec 26, 2023, 4:31PM
- Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Dec 26, 2023, 1:48PM
- Crude Oil Rises Over 3%; US Home Prices Increase In OctoberAvi Kapoor - Dec 26, 2023, 12:20PM
- Oncternal Therapeutics Reports Patient Death In Mid-Stage Blood Cancer Study Treated With Second Dose LevelVandana Singh - Dec 26, 2023, 11:41AM
- Dow Gains Over 50 Points; Chicago Fed National Activity Index Increases For NovemberAvi Kapoor - Dec 26, 2023, 9:39AM
- Oncternal Therapeutics Updates The Status Of Its Phase 1/2 Study Of ONCT-808, A ROR1-Targeting Autologous CAR T, In Patients With Relapsed Or Refractory Aggressive B-cell LymphomaHappy Mohamed - Dec 26, 2023, 9:02AM
Friday, December 22, 2023
Thursday, December 21, 2023
Friday, December 08, 2023
Thursday, December 07, 2023
Monday, December 04, 2023
Friday, November 10, 2023
Thursday, November 09, 2023
Wednesday, November 08, 2023
Thursday, October 26, 2023
Friday, October 06, 2023
Thursday, October 05, 2023
- Oncternal Therapeutics Announces First Patient Dosed In Phase 1/2 Study Of Dual-Action AR Inhibitor, ONCT-534, In Patients With Metastatic Castration-Resistant Prostate CancerBenzinga Newsdesk - Oct 5, 2023, 4:01PM
- Chief Technical Officer at Oncternal Therapeutics Exercises Options Worth $204KBenzinga Insights - Oct 5, 2023, 11:01AM
- Chief Executive Officer at Oncternal Therapeutics Exercises Options Worth $746KBenzinga Insights - Oct 5, 2023, 11:01AM
- Chief Medical Officer at Oncternal Therapeutics Acquires Company Stock Options Worth 782,075 SharesBenzinga Insights - Oct 5, 2023, 11:01AM
- Oncternal Therapeutics Chief Financial Officer Awarded $211K Worth of Stock OptionsBenzinga Insights - Oct 5, 2023, 11:01AM
Monday, September 18, 2023
- Promising Preclinical Results From Blood Cancer Propel Oncternal To Buy RatingVandana Singh - Sep 18, 2023, 3:00PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023Benzinga Insights - Sep 18, 2023, 11:00AM
- HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price TargetBenzinga Newsdesk - Sep 18, 2023, 6:31AM